Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Articles by Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Recent Updates to NCCN Guidelines on MF TreatmentPublished: July 6th 2021 | Updated:
Bone Marrow Transplant for Patients With MFPublished: July 20th 2021 | Updated:
Monitoring Disease Response or Progression in MFPublished: July 6th 2021 | Updated:
Fedratinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Ruxolitinib for Patients With Primary MyelofibrosisPublished: July 13th 2021 | Updated:
Primary Myelofibrosis: Trials of InterestPublished: July 7th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5